Social Behavior
Medicare Partially Covers Weight Loss Drugs Amidst High Price Concerns and Future Negotiation Prospects
Medicare, Obesity drugs, Wegovy, Semaglutide, Price negotiation, Affordability, Accessibility, Premium increases, Utilization management
Bayer Prepares Menopause Drug Rival to Astellas’ Veozah for Regulatory Filings Following Successful Phase 3 Trials
Bayer, Menopause Drug, Elinzanetant, Phase 3 Hat Trick, Regulatory Approval, Competition with Astellas’ Veozah
Bayer’s Menopause Drug Elinzanetant Achieves Successful Long-Term Results in Phase III Trial, Rivalling Astellas’ Veozah
Bayer, Elinzanetant, Menopause drug, Phase III trial, Long-term results, Hot flashes, Vasomotor symptoms, Astellas, Veozah, Competition
Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks
Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies
Gilead Sciences Strikes Deal with Merus for Trispecific Antibody Development
Gilead Sciences, Merus NV, Trispecific antibodies, T-Cell engager collaboration, Cancer therapy innovation
Biden Proposes Expansion of Medicare Drug Price Negotiation Program
Biden, Medicare, Drug Prices, Negotiation, Increased Scrutiny, More Drugs, Health Care Policy
Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership
Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million
AstraZeneca Abandons Roxadustat’s US Future while Retaining Collaboration with FibroGen in China
FibroGen, roxadustat, China, Ultrasonography, AstraZeneca, Collaboration, chemotherapy-induced anemia, Retained
Sanofi and Denali’s ALS Candidate SAR443820 Fails Phase 2 Trial
Amyotrophic Lateral Sclerosis, sanofi, SAR443820, Denali, Collaboration, Denali’s
Kyowa Kirin Partners with BridgeBio for Potential Achondroplasia Drug, Pays $100M in Pivotal Collaboration
Achondroplasia, infigratinib, BridgeBio, Kyowa, Kirin, Collaboration